- In January 2025, the U.S. Food and Drug Administration (FDA) approved Ozempic® (semaglutide) as the only glucagon-like peptide-1 receptor agonist (GLP-1 RA) indicated to reduce the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. This approval is based on the pivotal FLOW phase 3b kidney outcomes trial, which demonstrated a 24% relative risk reduction in kidney disease progression and cardiovascular and kidney mortality compared to placebo
